Plain-English translation of NCT06016088 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers studied , a new inhaled antibiotic designed to treat chronic lung infections in people with cystic fibrosis. The trial tested whether this medication, combined with a helper ingredient, was safe and how well it worked when inhaled directly into the lungs. Participants received either the new treatment or an active comparison medication for 14 days.
People with cystic fibrosis often develop persistent bacterial lung infections that are difficult to treat and can cause serious damage over time. This trial was designed to see if this medication could offer a better or additional treatment option for these chronic infections.
Participants inhaled the study medication or comparison medication through a nebulizer machine once daily for 14 days. They returned to the clinic for regular check-ins during the treatment period and were followed for an additional 14 days after finishing the medication to monitor their health. Blood and urine tests, breathing tests, and sputum samples were collected to assess safety and how well the treatment worked.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States